Appendix 3B

New issue announcement. application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12,

Name of entity	
----------------	--

Paladin Energy Ltd		
ABN		
47 061 681 098		

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- *Class of *securities issued or to be 1 issued
 - **Share Appreciation Rights**
- Number of +securities issued or to be issued (if known) or maximum number which may be issued

615,000

Principal terms of the *securities 3 (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Share Appreciation Rights (SARs) are issued under the terms of the company's existing Employee Performance Share Rights Plan as adopted by shareholders on 22 November 2012 (the Plan) for nil consideration. Share Appreciation Rights issued under the Plan are entitlements to acquire a number of Shares equal to the growth in the value of the underlying Shares (if any) upon satisfaction of the relevant vesting conditions and other terms and conditions determined by the Board under the Plan. Share Appreciation Rights granted under the Plan in relation to FY15 are subject to the following vesting conditions:

The Vesting Dates are as follows:

Tranche 1 - 50% of SARs will vest on

- 1 November 2016
- ii. Tranche 2 25% of SARs will vest on 1 November 2017.
- iii. Tranche 3 25% of SARs will vest on 1 November 2018.

Upon vesting of any Rights, participants will be issued with Shares equal to the value derived by multiplying the number of vested Rights exercised by the relative growth in share price over the deemed exercise price. Relative share price growth is determined by a comparison of the Paladin share price growth with a hurdle share price of 20 cents per share (calculated using Volume weighted average price (VWAP) of a Share for the five trading days before the date of exercise). Vested and exercised Share Appreciation Rights will be converted into Paladin ordinary shares. Unvested Share Appreciation Rights which do not meet the vesting conditions or are not exercised within the exercise period will automatically lapse.

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

No - Share Appreciation Rights are a different security from the existing class of quoted securities (ordinary shares) and therefore do not rank equally with them. Share Appreciation Rights do not confer on the holder an entitlement to vote at shareholder meetings, receive dividends or participate in pro-rata equity issues. Paladin shares which are allocated following the vesting and exercise of Share Appreciation Rights will rank equally in all respects with Paladin ordinary shares.

5 Issue price or consideration

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) Nil

Share Appreciation Rights (SARs) are issued under the terms of the company's existing Employee Performance Share Rights Plan as adopted by shareholders on 22 November 2012 (the Plan) for nil consideration and form part of the long term incentive component of employee remuneration

6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	No
	If Yes, complete sections 6b – 6h <i>in</i> relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of *securities issued under an exception in rule 7.2	N/A
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Rule 7.1 – 202,157,463 Rule 7.1A – N/A
7	⁺ Issue dates	31 March 2016
•	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	
	Cross reference: item 33 of Appendix 3B.	<u> </u>

		Number
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	1,712,716,2
		Number
9	Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)	8,052,500
		1,000,000

Number	+Class
1,712,716,422	Ordinary shares

Number	+Class
8,052,500	Share appreciation rights
1,000,000	Unlisted Options exercisable at \$0.20 and expiring 10/08/2018
1,000,000	Unlisted Options exercisable at \$0.20 and expiring 8/11/2018
1,000,000	Unlisted Options exercisable at \$0.20 and expiring 23/12/2018

Dividend policy (in the case of a N/A10 trust, distribution policy) on the increased capital (interests)

Part 2 - Pro rata issue

Is security holder approval required?	N/A
Is the issue renounceable or non-renounceable?	N/A
Ratio in which the *securities will be offered	N/A
•	
⁺ Class of ⁺ securities to which the offer relates	N/A
•	
⁺ Record date to determine entitlements	N/A
•	
Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
	required? Is the issue renounceable or non-renounceable? Ratio in which the *securities will be offered *Class of *securities to which the offer relates *Record date to determine entitlements Will holdings on different registers (or subregisters) be

⁺ See chapter 19 for defined terms.

17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A

30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Issue date	N/A
	3 - Quotation of securitie	
34	Type of *securities (tick one)	
(a)	*Securities described in Part	t ı
(b)	*	end of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible
	es that have ticked box 34(a)	
	cional securities forming a nev	
Tick to locum	indicate you are providing the informatents	tion or
35		securities, the names of the 20 largest holders of the the number and percentage of additional *securities
36		y securities, a distribution schedule of the additional umber of holders in the categories
37	A copy of any trust deed for	the additional *securities

Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought	N/A	
39	⁺ Class of ⁺ securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another +security, clearly identify that other +security)	N/A	
		Number	+Class
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	N/A	N/A

Quotation agreement

⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.

- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 31 March 2016

(Company secretary)
Print name: RANKO MATIC

+ See chapter 19 for defined terms. 397071

Appendix 3B Page 8 04/03/2013

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	1,666,927,668
Add the following:	163,265 (16 Sept 2015)
Number of fully paid +ordinary securities issued in that 12 month period under on	78,047 (29 Oct 2015)
issued in that 12 month period under an exception in rule 7.2	547,442 (3 Dec 2015)
Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval	
Number of partly paid +ordinary securities that became fully paid in that 12 month period	
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	-
"A"	1,667,716,422

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<i>Multiply</i> "A" by 0.15	250,157,463	
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule	
Insert number of +equity securities issued	45,000,000 (6 Aug 2015)	
or agreed to be issued in that 12 month period <i>not counting</i> those issued:	3,000,000 (8 March 2016)	
Under an exception in rule 7.2		
Under rule 7.1A		
 With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	48,000,000	
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining	
"A" x 0.15	250,157,463	
Note: number must be same as shown in Step 2		
Subtract "C"	48,000,000	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	202,157,463	
	[Note: this is the remaining placement capacity under rule 7.1]	

opendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms. 397071 Appendix 3B Page 10

Part 2

Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
Multiply "A" by 0.10	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used	
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	

04/03/2013 Appendix 3B Page 11

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	
Note: number must be same as shown in Step 2	
Subtract "E"	
Note: number must be same as shown in Step 3	
Total ["A" x 0.10] – "E"	
	Note: this is the remaining placement capacity under rule 7.1A